Calcitonin Gene-Related Peptide (CGRP) Antagonists
Also known as: CGRP monoclonal antibodies, CGRP receptor antagonists, Calcitonin gene-related peptide inhibitors
Peptide antagonists targeting CGRP receptors to reduce migraine frequency and pain signaling. Multiple FDA-approved monoclonal antibodies with peptide-based mechanisms.
On This Page
Research Status
FDA-approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Erythema, induration, or pruritus at injection site. Usually resolves within 24-48 hours. Rotate injection sites to minimize recurrence.
Reported in clinical trials, particularly with erenumab. Increase fluid and fiber intake; contact healthcare provider if persistent.
Upper respiratory tract infection symptoms. May reflect general immune function rather than direct drug effect.
Some patients develop anti-drug antibodies, which may reduce efficacy over time. Incidence varies by specific CGRP antagonist (lower with erenumab, higher with fremanezumab).
Some patients experience rebound increase in migraine frequency after stopping CGRP antagonists. Gradual discontinuation may be preferable.
Anaphylaxis or severe allergic reactions reported rarely. Seek immediate medical attention if experiencing difficulty breathing, swelling of face/throat, or severe rash.
Theoretical concern due to CGRP's role in vasodilation; however, clinical trials have not demonstrated increased cardiovascular events. Use with caution in patients with coronary vasospasm or uncontrolled hypertension.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 120-240 mg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Half-life | Erenumab: 28 days; Fremanezumab: 30 days; Eptinezumab: 38 days |
CGRP antagonists are monoclonal antibodies that bind to and block calcitonin gene-related peptide (CGRP) or its receptor. CGRP is a neuropeptide involved in migraine pathophysiology, particularly in pain signal transmission and neuroinflammation. By blocking CGRP signaling, these antibodies reduce migraine frequency, duration, and severity in both episodic and chronic migraine patients.
Track your Calcitonin Gene-Related Peptide (CGRP) Antagonists research
Free account. No credit card required.
Recent Research
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Calcitonin Gene-Related Peptide (CGRP) Antagonists is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.